BU-NOT-SET

CONTACT US
Modified release fixed dose combination product with two poorly soluble drug substances
  • Drug product
pellets
Case study
Patient centricity during drug development and commercialisation
  • Drug product
Eyes
Insight
10 considerations to kick-start your drug development journey
  • Drug product
Eyes
Insight
Guidance for start-ups on drug development
  • Drug product
Eyes
Insight
Drug development for start-ups
  • Drug product
  • Drug substance
Test tubes
White paper
Optimising environmental sustainability
  • Sustainability
Eyes
Insight
Adapting to deal with the COVID-19 pandemic
  • Industry trends
Eyes
Insight
On Drug Delivery – Sustainability Q&A
  • Sustainability
Eyes
Insight
Optimising analytical chemistry to improve speed to market
  • Analytical chemistry
Man lab
Insight
Insight
  • Biologics
Unlocking the potential of RNA therapeutics through innovation and collaboration
White paper
  • Analytical chemistry
Using in vitro release testing (IVRT) to analyse semi-solid topical formulations
Insight
  • Biologics
Enhancing the production of RNA with continuous manufacturing
Fact sheet
  • Drug product
GERTEIS MINI-PACTOR® Advanced dry granulation services
Case study
  • Biologics
Overcoming oncolytic virus therapy production challenges through collaboration
Insight
  • Industry trends
Emerging trends set to impact drug development in 2024
Webinar
  • Biologics
Webinar: ATMPs in focus: Essential CMC strategies for every phase
Insight
  • Drug product
  • Industry trends
Trends set to make an impact on oral solid dose development in 2024
Insight
  • Biologics
Enhancing AAV therapy development and manufacture with a platform approach